NCT01564563 is a Phase 2 clinical trial of standard therapy in Acquired Bleeding Disorder, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT01564563?

NCT01564563 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT01564563?

Interventions in NCT01564563: standard therapy, placebo, activated recombinant human factor VII, activated recombinant human factor VII.

What condition does NCT01564563 study?

NCT01564563 studies Acquired Bleeding Disorder, Bleeding During/Following Surgery.

Is NCT01564563 still recruiting?

NCT01564563 is currently terminated. Last updated 27 February 2017.

Last reviewed 2017-02-27 · How we verify

NCT01564563

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Terminated Phase 2 Last updated 27 February 2017

What this trial tests

Phase 2 trial testing standard therapy in Acquired Bleeding Disorder in 11 participants. Terminated before completion.

Timeline

28 June 2002

Primary endpoint
27 October 2003

27 October 2003

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	11
Start date	28 June 2002
Primary completion	27 October 2003
Estimated completion	27 October 2003
Sites	7 locations across United States

Drugs / interventions tested

standard therapy — full drug profile →
placebo
activated recombinant human factor VII — full drug profile →
activated recombinant human factor VII — full drug profile →

Conditions studied

Acquired Bleeding Disorder — all drugs for Acquired Bleeding Disorder →
Bleeding During/Following Surgery — all drugs for Bleeding During/Following Surgery →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

12 and older, any sex, with Acquired Bleeding Disorder or Bleeding During/Following Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of standard therapy

Trials testing the same drug.

NCT05247203 — Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus · Phase 1 · completed
NCT05305625 — Effect of Remote Ischemic Postcondioning on Glymphatic System in Acute Stroke · NA · unknown
NCT05552313 — Effects of Kinesio Taping With Thoracic Manipulation in Mechanical Neck Pain Patients. · NA · unknown
NCT05781945 — COVID-19 Pneumonia and Gut Inflammation · NA · completed
NCT05795972 — Inulin Supplementation in Patients With Type 1 Diabetes · NA · unknown

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01564563 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 27 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01564563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing